Skip to main content

Sensitive and differential blood and cerebrospinal fluid test for neurodegenerative dementia diagnosis

Objective

The project aims to develop an integrated system allowing differential diagnosis of neurodegenerative diseases based on several patented, sensitive and robust technologies. This system uses an ultrasensitive detection of specific direct and indirect amyloid-related markers in the cerebrospinal fluid and in blood, with new derivative products of nano/micro biosciences. Among diseases with amyloid deposits, the NeuroScreen project will focus on Alzheimer and Prion diseases for which some ambiguities still exist regarding their differential diagnosis. At present, their diagnosis must be confirmed by post-mortem cerebral analysis. The experimental work is broken into 7 workpackages management being gathered in a WP0, with the corresponding objectives being achievable within the 36 months of the project: WP1 Design, optimisation and production of the early test; aim: neuroaptamer prototypes, neuro-strips, neuro-magnetic beads, validation of packaging and sterilization process, and stabilised and validated supports. WP2 Alzheimer Diagnostic: Tau-181 and -231 markers; aim: choice of the marker candidate and the prototype to be tested in a multiplex trial. WP3 Dementia diagnostic and Lewy bodies: -synuclein marker; aim: development and validation of a suitable assay for -synuclein oligomers. WP4 Creutzfeldt-Jakob: PRION; aim: validation of aptamers, neurostrips and i-PCR. WP5 Therapeutic follow-up; aim: biological markers for future therapeutic follow-up validation WP6 Integrative section and fundamental knowledge derived from the other WPs; aim: validation of the multiplex assays systems. WP7 Accompaniment and regulatory follow-up. The work will be carried out by a consortium made up of 12 partners, coming from 6 European member-states. A complementary expertise and a multidisciplinary partnership of high quality has been gathered with academics, research centres, 1 technology transfer center, 2 hospitals, 2 industrial SMEs and 1 SME expert in regulatory aspects.

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

UNIVERSITÉ DE LIÈGE
Address
Place Du Xx Août, 7
Liege
Belgium

Participants (11)

ASSOCIATION POUR LES TRANSFERTS DE TECHNOLOGIE DU MANS
France
Address
20 Rue Thalès De Milet
Le Mans
EUDICA
France
Address
1 Avenue Du Pré Closet - Pae Des Glaisins
Annecy-le-vieux
ALCIS
France
Address
8A Chemin De Palente
Besançon
AJ ROBOSCREEN GMBH
Germany
Address
Delitzscher Strasse, 135
Leipzig
HOSPICES CIVILS DE LYON
France
Address
3, Quai Des Célestins
Lyon
INSTITUT JOZEF STEFAN
Slovenia
Address
39 Jamova
Ljubljana
LANCASTER UNIVERSITY
United Kingdom
Address
Lancaster University, Bailrigg
Lancaster (Lancashire)
ORSZAGOS PSZICHIATRIAI ES NEUROLOGIAI INTEZET
Hungary
Address
116 Hüvösvölgyi Ut
Budapest
MEDIZINISCHE UNIVERSITAET WIEN
Austria
Address
Spitalgasse 23
Wien
CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
Germany
Address
Schumannstr. 20-21
Berlin
UNIVERSITÉ DU MAINE
France
Address
Université Du Maine, Avenue O. Messian
Le Mans